Human cardiac microvascular and macrovascular endothelial cells respond differently to oxidatively modified LDL

Atherosclerosis

Volumn 137, Issue 1, 1998, Pages 87-95

  Gräfe, Michael ^a   Auch Schwelk, Wolfgang ^a   Hertel, Hartmut ^a   Terbeek, Dirk ^a   Steinheider, Gerhard ^b   Loebe, Matthias ^a   Fleck, Eckart ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b Fed Inst Drugs and Med Devices   (Germany)

Author keywords

Endothelial cells; LDL; Plasminogen activator inhibitor; Tissue plasminogen activator

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROBUCOL; PROCOAGULANT; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CONTROLLED STUDY; CORONARY BLOOD VESSEL; HUMAN; HUMAN CELL; LIPID OXIDATION; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

ANTIOXIDANTS; BLOOD COAGULATION FACTORS; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; LIPOPROTEINS, LDL; PEPTIDYL-DIPEPTIDASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0032478226     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00258-X     Document Type: Article

References (45)

1. Hamsten A., Faire U., Walldius G. et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 3:1987;9.
2. Falk E., Fernandez-Ortiz A. Role of thrombosis in atherosclerosis and its complications. Am J Cardiol. 75:1995;5B-11B.
3. Ylä-Herttuala S., Palinski W., Butler S.W., Picard S., Steinberg D., Witztum J.L. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 14:1994;32-40.
4. Galle J., Bassenge E., Busse R. Oxidized low density lipoproteins potentiate vasoconstrictions to various agonists by direct interaction with vascular smooth muscle. Circ Res. 66:1990;1287-1293.
5. Kim J.A., Territo M.C., Carlos T.M. et al. Partial characterization of leukocyte binding molecules on endothelial cells induced by minimally oxidized LDL. Arterioscler Thromb. 14:1994;427-433.
6. Malden L.T., Chait A., Raines E.W., Ross R. The influence of oxidatively modified low density lipoproteins on expression of platelet-derived growth factor by human monocyte-derived macrophages. J Biol Chem. 266:1991;13901-13907.
7. Fei H., Berliner J.A., Parhami F., Drake TA. Regulation of endothelial cell tissue factor expression by minimally oxidized LDL and lipopolysaccharide. Arterioscler Thromb. 13:1993;1711-1717.
8. Parry GCN., Mackman N. Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb. 15:1995;612-621.
9. Latron Y., Chautan M., Anfosso F. et al. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb. 11:1991;1821-1829.
10. Tremoli E., Camera M., Maderna P. et al. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. Arterioscler Thromb. 13:1993;338-346.
11. Kugiyama K., Sakamoto T., Misumi I. et al. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue- type plasminogen activator release from endothelial cells. Circ Res. 73:1993;335-343.
12. Levin E.G., Miles L.A., Fless G.M. et al. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb. 14:1994;438-442.
13. Auch-Schwelk W., Kuchenbuch C., Claus M. et al. Local regulation of vascular tone by bradykinin and converting enzyme inhibitors. Eur Heart J. 14:1993;154-160.
14. Miller V.M., Vanhoutte P.M. Heterogeneity in endothelium-dependent relaxations. Vanhoutte P.M.V. Relaxing and Contracting Factors. 1988;285-307 The Humana Press, Clifton, NJ.
15. Gräfe M., Auch-Schwelk W., Graf K. et al. Isolation and characterization of macrovascular and microvascular endothelial cells from human hearts. Am J Physiol. 267:1994;H2138-H2148.
16. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 43:1955;1345-1353.
17. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J Biol Chem. 193:1951;265-275.
18. Siedel J., Hägele O., Ziegenhorn J., Wahlefeld A.W. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem. 29:1983;1075-1080.
19. Wahlefeld A.W. Methoden der enzymatischen. Bergmeyer H.U. Analyse. 1974;1878-1878 Verlag Chemie, Weinheim.
20. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
21. Wray W., Boulikas T., Wray V.P., Hancock R. Silver staining of proteins in polyacrylamide gels. Anal Biochem. 118:1981;197-203.
22. Fong K.-L., McCay P.B., Poyer J.L. Evidence that peroxidation of lysosomal membranes is initiated by hydroxyl free radicals produced during flavin enzyme activity. J Biol Chem. 248:1973;7792-7797.
23. Rijken D.C., Juhan-Vague I., De Cock F., Collen D. Measurement of human tissue-type plasminogen activator by a two- site immunoreactive assay. J Lab Clin Med. 101:1983;274-284.
24. Wiman B., Chmielewska J., Ranby M. Inactivation of tissue plasminogen activator in plasma: demonstration of a complex with a new rapid inhibitor. J Biol Chem. 259:1984;3644-3647.
25. Friedland J., Silverstein E. A sensitive fluorimetric assay for serum angiotensin-converting enzyme. Am J Clin Pathol. 66:1976;416-424.
26. Kapiloff M.S., Strittmatter S.M., Fricker L.D., Snyder S.H. A fluorometric assay for angiotensin-converting enzyme activity. Anal Biochem. 140:1984;293-302.
27. Moll T., Czyz M., Holzmüller H. et al. Regulation of the tissue factor promotor in endothelial cells. J Biol Chem. 270:1995;3849-3857.
28. Spanel-Borowski K., van der Bosch J. Different phenotypes of cultured microvessel endothelial cells obtained from bovine corpus luteum. Cell Tissue Res. 261:1990;35-47.
29. Zakrzewicz A., Gräfe M., Terbeek D. et al. L-selectin-dependent leukocyte adhesion to microvascular but not to macrovascular endothelial cells of human coronary endothelial cells. Blood. 89:1997;3228-3235.
30. Gräfe M, Auch-Schwelk W, Zakrzewicz A et al. Angiotensin II induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res. 81:1997;804-811.
31. Khan B.V., Parthasarathy S.S., Alexander R.W., Medford R. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest. 95:1995;1262-1270.
32. Rajavashisth T.B., Andalibi A., Territo M.C. et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature. 344:1990;254-257.
33. Cushing S.D., Berliner J.A., Valente A.J et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA. 87:1990;5134-5138.
34. Couffinhal T., Duplàa C., Labat L., Moreau C., Bietz I., Bonnet J. Effect of low density lipoprotein on monocyte adheveness to endothelial cells in vitro. Atherosclerosis. 99:1993;35-45.
35. Lehr H.A., Seemüller J., Hübner C., Menger M.D., Messmer K. Oxidized LDL-induced leukocyte/endothelium interaction in vivo involves the receptor for platelet-activating factor. Arterioscler Thromb. 13:1993;1013-1018.
36. Kugiyama K., Ohgushi M., Sugiyama S. et al. Lysophophatidycholin inhibits surface receptor-mediated intercellular signals in endothelial cells by a pathway involving protein kinase C activation. Circ Res. 71:1992;1422-1428.
37. Coffey M.D., Cole R.A., Colles S.M., Chisolm G.M. In vitro injury by oxidized low density lipoprotein involves lipid hydroperoxide-induced formation of alkoxyl, lipid, and peroxyl radicals. J Clin Invest. 96:1995;1866-1873.
38. Jougasaki M., Kugiyama K., Saito Y., Nakao K., Imura H., Yasue H. Suppression of endothelin-1 secretion by lysophosphatidylcholine in oxidized low density lipoprotein in cultured vascular endothelial cells. Circ Res. 71:1992;614-619.
39. Natarajan N. Oxidants and signal transduction in vascular endothelium. J Lab Clin Med. 125:1995;26-37.
40. Carew T.E., Schwenke D.C., Steinberg D. Antiatherogenc effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA. 84:1987;7725-7729.
41. Anderson T.J., Meredith I.T., Charbonneau F. et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation. 93:1996;1647-1650.
42. Tardif J.-C., Cote G., Lesperance J. et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. New Engl J Med. 337:1997;365-372.
43. Masuda T., Yasue H., Ogawa H. et al. Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina. Am Heart J. 124:1992;314-319.
44. Masuda J., Ross R. Atherogenesis during low level hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque. Arterioscler Thromb. 10:1990;178-187.
45. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s [Review]. Nature. 362:1993;801-809.